<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>The molecular biology of melanoma</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">The molecular biology of melanoma</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">The molecular biology of melanoma</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ryan J Sullivan, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alexander N Shoushtari, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael B Atkins, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Melinda Yushak, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 11, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H5643571"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Melanoma is among the most common cancers in the United States, causing approximately 98,000 new cases and 8000 deaths annually [<a href="#rid1">1</a>]. Worldwide, melanoma accounts for approximately 300,000 new cases and 60,000 deaths annually [<a href="#rid2">2</a>]. (See  <a class="medical medical_review" href="/d/html/4844.html" rel="external">"Melanoma: Epidemiology and risk factors", section on 'Epidemiology'</a>.)</p><p>A majority of patients with localized disease can be treated successfully with surgical resection. Individuals who present with or subsequently develop distant metastases are typically treated with systemic therapy, such as checkpoint inhibitor immunotherapy or molecularly targeted therapy. (See  <a class="medical medical_review" href="/d/html/85841.html" rel="external">"Overview of the management of advanced cutaneous melanoma"</a>.)</p><p>An increasing understanding of melanocyte biology and melanoma pathogenesis has led to the development of targeted therapies and has the potential for continued major improvements in the care of patients with advanced melanoma. The most important breakthroughs have been the discovery of the mitogen-activated protein kinase (MAPK) pathway as the key signaling pathway, and the critical role of microphthalmia-associated transcription factor (MITF).</p><p>This topic provides an overview of melanocyte biology and the important molecular alterations of genes and signaling pathways that are critical to the<em> </em>development and pathogenesis of melanoma. The clinical results of targeted agents that are developed based upon this information are discussed separately. (See  <a class="medical medical_review" href="/d/html/15408.html" rel="external">"Systemic treatment of metastatic melanoma with BRAF and other molecular alterations"</a>.)</p><p class="headingAnchor" id="H5643578"><span class="h1">MELANOCYTE BIOLOGY</span><span class="headingEndMark"> — </span>Melanocytes are the pigment-containing cells of the skin that produce melanin in response to stimuli such as ultraviolet (UV) radiation. Melanocytes also make the pigment that determines skin and hair color.</p><p>Melanocytes are derived from pluripotent neural crest stem cells. Melanocyte development is modulated by KIT and microphthalmia-associated transcription factor (MITF), factors that are mutated or amplified oncogenes in a fraction of melanomas [<a href="#rid3">3</a>].</p><p>Alpha-melanocyte stimulating hormone (MSH) is a propigmentation peptide that stimulates the melanocortin 1 receptor (MC1R) on the surface of melanocytes [<a href="#rid4">4</a>]. The <em>MC1R</em> gene exists in numerous variant (polymorphic) forms; nonsignaling variants produce the red hair/fair skin phenotype, which is associated with an increased risk of melanoma and nonmelanoma skin cancers [<a href="#rid5">5</a>].</p><p>Intracellular cAMP induction downstream of MC1R activates the expression of MITF, which stimulates transcription of numerous genes that participate in the conversion of tyrosine into melanin pigments. Stimulation of cutaneous pigmentation following UV exposure (tanning) is thought to occur via keratinocyte DNA damage, p53-mediated induction of proopiomelanocortin (POMC)/MSH expression, followed by secretion of MSH and stimulation of MC1R in epidermal melanocytes [<a href="#rid6">6</a>].</p><p>Cutaneous UV exposure may induce behavioral effects, perhaps related to endorphin components of the POMC/MSH complex, which may produce an addiction to sun bathing and, therefore, contribute to the increase in melanoma incidence observed over recent decades [<a href="#rid7">7</a>]. "Rescue" of this cAMP-MITF-pigment cascade has been achieved via topical drug delivery in mouse models and confers protection against UV-induced carcinogenesis [<a href="#rid8">8,9</a>].</p><p class="headingAnchor" id="H5643585"><span class="h1">MAPK PATHWAY</span><span class="headingEndMark"> — </span>The mitogen-activated protein kinase (MAPK) pathway is activated in almost all melanomas  (<a class="graphic graphic_figure graphicRef53134" href="/d/graphic/53134.html" rel="external">figure 1</a>) [<a href="#rid10">10</a>]. In nonmalignant cells, the interaction between a growth factor receptor and its ligand is required to activate this pathway. This leads to a series of events that promote cellular growth and survival. The RAS family members are G-proteins, which serve as critical mediators in the transduction of such signals.</p><p>Results of The Cancer Genome Atlas (TCGA) and other large scale genomic analysis efforts in melanoma have identified hot spot mutations in <em>NRAS</em> in 25 to 30 percent of cutaneous melanomas, which are thought to be important drivers of oncogenesis [<a href="#rid11">11,12</a>]. A somatic mutation in the <em>NRAS</em> gene can cause constitutive activity of the NRAS protein, which is thus incapable of being "turned off." This leads to the serial activation of serine/threonine kinases, which promotes cell cycle progression, cellular transformation, and increased cell survival. In addition, this cascade of events may be mediated through the overexpression and/or hyperactivation of various growth factor receptors, such as c-Met, epidermal growth factor receptor (EGFR), and KIT, as well as through the loss of function of the <em>NF1</em> tumor suppressor gene that acts to suppress NRAS signaling [<a href="#rid13">13-16</a>]. In fact, the <em>NF1</em> mutation is considered a third major genomic subset of cutaneous melanomas, behind <em>BRAF</em> and <em>NRAS</em> mutations, and is present in 13 to 14 percent of cases [<a href="#rid11">11,12</a>]. These subsets are largely but not entirely mutually exclusive, and cutaneous melanomas may harbor activating alterations in more than one of these genes (eg, coalterations <em>in NF1</em> and <em>NRAS</em>) [<a href="#rid11">11</a>].</p><p>The most important downstream mediators of activated RAS are the serine/threonine kinases BRAF and CRAF, which are activated following RAS binding  (<a class="graphic graphic_figure graphicRef53134" href="/d/graphic/53134.html" rel="external">figure 1</a>) [<a href="#rid17">17,18</a>]. In contrast to BRAF, activation of the pathway by CRAF requires additional steps, whereas activation of BRAF alone is sufficient. This may explain why an activating mutation in the BRAF kinase domain is present in 40 to 50 percent of patients with melanoma, but there are no descriptions of activating mutations of CRAF [<a href="#rid19">19-21</a>].</p><p>Following activation, RAF, typically in the form of either a homo- or heterodimer, interacts with the MAPK/extracellular signal-regulated kinase (ERK) kinase MEK, thereby initiating MEK phosphorylation, which in turn leads to an activating phosphorylation of ERK, its only known substrate [<a href="#rid17">17,22,23</a>]. The activation of ERK leads to a pro-growth and transforming signal, through its interaction with a number of molecules, which appears to be critical to the pathogenesis of many malignancies.</p><p class="headingAnchor" id="H220469"><span class="h2">Molecular characterization of melanocytic lesions</span><span class="headingEndMark"> — </span><em>BRAF</em> mutations appear to be an acquired event that occurs in early invasive melanoma and leads to clonal expansion and tumor progression. The <em>BRAF</em> mutation, thus, is not a founder event but rather facilitates malignant transformation with the acquisition of subsequent oncogenic stimuli. Evidence supporting this interpretation includes the following:</p><p class="bulletIndent1"><span class="glyph">●</span><em>BRAF</em> mutations are common in melanocytic nevi, vertical growth phase melanomas, and metastatic melanoma (70 to 80, 40 to 50, and 40 to 50 percent, respectively). However, <em>BRAF</em> mutations are rarely detected in radial growth phase melanomas or in situ melanoma (10 and 6 percent, respectively), which are thought to be the initial malignant lesions prior to development of frankly invasive lesions [<a href="#rid21">21,24-26</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Polyclonality (ie, <em>BRAF</em> mutated cells mixed with <em>BRAF</em> wild-type cells) has been observed in both atypical nevi and primary melanomas, though such polyclonality has not been seen in individual metastatic tumors nor in tumors from distinct sites in an individual patient [<a href="#rid10">10,27,28</a>].</p><p></p><p>These findings can be viewed as contradicting the popularly held belief that <em>BRAF</em> mutation precedes all other oncogenic events in <em>BRAF</em> mutant melanoma, based primarily on the fact that <em>BRAF</em> mutations are present in 70 to 80 percent of dysplastic nevi [<a href="#rid24">24</a>]. However, the precise relationship between nevi and melanomagenesis remains incompletely understood. Further elucidation of the mechanisms of transformation in <em>BRAF</em> mutant melanoma is needed. Irrespective of the mechanism, however, when these <em>BRAF</em> mutations occur in invasive melanoma, the resultant constitutive activation of MEK (and subsequently ERK) leads to oncogenesis through the promotion of cellular growth and opposition of apoptosis, as well as to the strict reliance of these cells upon the signaling cascade [<a href="#rid29">29</a>].</p><p class="headingAnchor" id="H220084"><span class="h2">Genetic abnormalities in melanoma</span><span class="headingEndMark"> — </span>Genomic mutations and/or aberrations are present in the majority of melanomas [<a href="#rid10">10-12,30</a>]. These can lead to activation of the MAPK pathway and create an oncogenic addiction to the mutated or hyperactivated protein. Within this pathway, the patterns of mutation frequencies for each subtype differ significantly [<a href="#rid30">30-38</a>].</p><p class="headingAnchor" id="H219765"><span class="h3">Cutaneous melanoma and precursor lesions</span><span class="headingEndMark"> — </span>In cutaneous melanoma, <em>BRAF</em> and <em>NRAS</em> mutations are the most frequently observed (40 to 50 and 15 to 20 percent of cases, respectively) [<a href="#rid21">21,39-42</a>]. <em>BRAF</em> and <em>NRAS</em> mutations are more common in cutaneous melanomas without chronic sun damage (CSD) compared with those associated with CSD (60 versus 6 to 22 percent and 20 to 22 versus 0 to 15 percent, respectively), whereas mutations in c-kit are more common in CSD skin than in non-CSD skin (15 to 30 versus &lt;1 percent in White individuals and up to 11 percent in Asian populations) [<a href="#rid30">30,43,44</a>]. Except in rare cases and in the setting of BRAF inhibitor therapy resistance, activating <em>BRAF</em>, <em>NRAS</em>, and <em>c-kit </em>mutations are mutually exclusive [<a href="#rid45">45</a>]. Additionally, <em>BRAF</em> V600E mutations are more common in females, younger patients, and in non-CSD skin than the second most common <em>BRAF</em> mutation <em>BRAF</em> V600K [<a href="#rid46">46,47</a>].</p><p>Analysis of adjacent precursor lesions (nevi) together with invasive melanomas helped to assign information regarding the order of acquisition of melanoma mutations [<a href="#rid48">48</a>]. Unequivocally, benign nevi were seen to contain <em>BRAF</em> V600E in all cases studied. Additionally, 77 percent of intermediately aggressive precursors or frankly invasive lesions contained telomerase reverse transcriptase (TERT) promoter mutations. Loss of both cyclin-dependent kinase inhibitor 2A (CDKN2A) alleles and occurrence of genomic copy number alterations were observed only in invasive melanomas.</p><p class="headingAnchor" id="H3885807871"><span class="h3">Classification of BRAF mutations</span><span class="headingEndMark"> — </span>Our understanding of <em>BRAF</em> signaling has improved, leading to a more accurate but complex categorization of MAPK driver alterations in cutaneous melanomas beyond <em>BRAF</em>, <em>NRAS</em>, and <em>NF1</em> [<a href="#rid49">49</a>]. Physiologic <em>BRAF </em>signaling in melanocytes occurs through ERK via BRAF-BRAF homodimers and BRAF-CRAF heterodimers. In turn, ERK serves as an important feedback regulator to BRAF via upstream inhibition of RTKs and RAS-mediated BRAF/CRAF heterodimer signaling to maintain homeostasis. </p><p>Studies of <em>BRAF</em> signaling have identified three main classes of oncogenic <em>BRAF</em> alterations that alter this relationship and achieve RAS-independent growth signaling in distinct, therapeutically relevant ways [<a href="#rid50">50,51</a>]. Among cutaneous melanomas with <em>BRAF</em> mutations, a majority are class 1 alterations (90 to 95 percent), although additional activating <em>BRAF</em> (class 2 and 3) alterations have also been described (5 to 10 percent).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Class 1 alterations </strong>– Class 1 alterations are <em>BRAF</em> V600 alterations to -E, -K, or less often -R and represent the most common single MAPK driver alteration in cutaneous melanomas. Other rare <em>BRAF</em> V600 amino acid mutations (eg, M-, D-, and G-) are also considered to be class 1 alterations. (See  <a class="medical medical_review" href="/d/html/15408.html" rel="external">"Systemic treatment of metastatic melanoma with BRAF and other molecular alterations", section on 'BRAF V600 mutation variants'</a>.)</p><p></p><p class="bulletIndent1">This mutation results in BRAF monomers (rather than physiologic dimers) that signal downstream through MEK and ERK and are insensitive to ERK-mediated feedback inhibition of RAS-mediated BRAF homo- and heterodimerization. Inhibitors of both BRAF monomers (<a class="drug drug_general" data-topicid="16798" href="/d/drug information/16798.html" rel="external">vemurafenib</a>, <a class="drug drug_general" data-topicid="89686" href="/d/drug information/89686.html" rel="external">dabrafenib</a>) and MEK (<a class="drug drug_general" data-topicid="89685" href="/d/drug information/89685.html" rel="external">trametinib</a>) have been shown to prolong overall survival in patients with cutaneous, derived, advanced melanoma containing the mutations in <em>BRAF</em> V600. Furthermore, combination therapy with BRAF and MEK inhibitors (dabrafenib plus trametinib, vemurafenib plus <a class="drug drug_general" data-topicid="105354" href="/d/drug information/105354.html" rel="external">cobimetinib</a>, <a class="drug drug_general" data-topicid="118325" href="/d/drug information/118325.html" rel="external">encorafenib</a> plus <a class="drug drug_general" data-topicid="118324" href="/d/drug information/118324.html" rel="external">binimetinib</a>) is more effective than single-agent BRAF inhibitor therapy, without a substantial increase in toxicity. (See  <a class="medical medical_review" href="/d/html/15408.html" rel="external">"Systemic treatment of metastatic melanoma with BRAF and other molecular alterations", section on 'Choice of BRAF plus MEK inhibitor therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Class 2 alterations</strong> – Class 2 alterations, which include missense mutations such as K601E and D597N as well as oncogenic BRAF fusions, alter the RAS-binding domain such that they are insensitive to physiologic inhibition by ERK similar to class 1 alterations; however, they signal efficiently as mutant homodimers [<a href="#rid50">50</a>]. As a result, BRAF monomer inhibitors like <a class="drug drug_general" data-topicid="16798" href="/d/drug information/16798.html" rel="external">vemurafenib</a> would paradoxically activate class 2 mutant homodimer signaling. Clinical trials are ongoing in the use of inhibitors of BRAF dimer signaling in advanced melanomas. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Class 3 alterations</strong> – Class 3 alterations include BRAF D594N, which abrogates the kinase activity of BRAF signaling and leads to low ERK signaling. Its oncogenic potential lies in the loss of feedback inhibition of upstream RTKs rather than high BRAF kinase activity seen in class 1 and 2 lesions [<a href="#rid51">51</a>]. As a result, BRAF class 3 mutant melanomas are frequently coaltered with upstream RTK or RAS drivers of the MAPK pathway such as <em>NRAS</em>, <em>KIT</em>, or <em>NF1</em>. Successful targeted inhibition of these tumors may lie in targeting the upstream "amplified" driver activity. </p><p></p><p class="headingAnchor" id="H219772"><span class="h3">Uveal melanomas</span><span class="headingEndMark"> — </span>The molecular pathogenesis of uveal melanoma is distinct from that of cutaneous melanoma and other melanoma subtypes, including conjunctival melanoma. Advances in understanding the molecular pathogenesis of uveal melanoma may eventually provide important opportunities for targeted therapy in patients with metastatic disease. (See  <a class="medical medical_review" href="/d/html/113047.html" rel="external">"Metastatic uveal melanoma"</a>.)</p><p class="headingAnchor" id="H221642017"><span class="h4">Overview</span><span class="headingEndMark"> — </span>The genomic landscape of uveal melanoma is characterized by a small number of highly recurrent mutations arranged in two clusters [<a href="#rid52">52</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mutations without prognostic relevance</strong> – An early cluster of mutually exclusive initiating mutations in <em>GNAQ</em>, <em>GNA11</em>, <em>PLCB4</em>, and <em>CYSLTR2</em> are present in &gt;95 percent of uveal melanomas and are not prognostically relevant. (See <a class="local">'Mutations without prognostic relevance'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mutations with prognostic relevance</strong> – By contrast, a second cluster of near mutually exclusive "progression mutations" in <em>BAP1</em>, <em>SF3B1</em>, and <em>EIF1AX</em> are present in patients with primary uveal melanoma, appear to have prognostic significance, and are used to determine post-treatment surveillance. (See <a class="local">'Mutations with prognostic relevance'</a> below and  <a class="medical medical_review" href="/d/html/7617.html" rel="external">"Initial management of uveal and conjunctival melanomas", section on 'Posttreatment systemic surveillance'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong><em>BAP1</em></strong><strong> </strong>– <em>BAP1</em> mutations occur in almost 50 percent of patients (with 2 to 3 percent of patients harboring germline <em>BAP1</em> mutations) and are associated with the highest risk of metastases [<a href="#rid31">31,32,53</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong><em>SF3B1 </em></strong>– <em>SF3B1</em> mutations are present in approximately 19 to 30 percent of patients and are associated with an intermediate risk of metastases [<a href="#rid52">52,54,55</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong><em>EIF1AX</em></strong><strong> </strong>– <em>EIF1AX</em> mutations occur in approximately 15 to 24 percent of patients and are associated with the lowest risk of metastases [<a href="#rid33">33,52,56-58</a>].</p><p></p><p>Importantly, uveal melanomas rarely if ever harbor mutations in<em> BRAF</em>, <em>NRAS</em>,<em> KIT</em>, or other recurrent alterations seen in cutaneous melanoma [<a href="#rid31">31,32</a>]. (See  <a class="medical medical_review" href="/d/html/15408.html" rel="external">"Systemic treatment of metastatic melanoma with BRAF and other molecular alterations"</a>.)</p><p>While most uveal melanomas have a low mutational burden [<a href="#rid52">52,58</a>], a small subset with germline mutations in the DNA base excision repair factor MBD4 have a high mutation burden and may be more likely to respond to checkpoint inhibitor immunotherapy [<a href="#rid59">59</a>]. (See  <a class="medical medical_review" href="/d/html/120646.html" rel="external">"Tissue-agnostic cancer therapy: DNA mismatch repair deficiency, tumor mutational burden, and response to immune checkpoint blockade in solid tumors", section on 'Tumors with high mutational burden'</a>.)</p><p class="headingAnchor" id="H1067610134"><span class="h4">Mutations without prognostic relevance</span><span class="headingEndMark"> — </span>Mutually exclusive mutations in <em>GNAQ</em>, <em>GNA11</em>, <em>PLCB4</em>, and <em>CYSLTR2</em> are frequently present in uveal melanoma, but lack prognostic significance.</p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>GNAQ</em></strong><strong> and </strong><strong><em>GNA11</em></strong> – In patients with uveal melanoma, the MAPK pathway is upregulated by activating point mutations in either of the homologous G-proteins GNAQ or GNA11, which together are observed <strong>in over 90 percent of uveal melanomas</strong> [<a href="#rid31">31,32,53-55</a>]. These mutations are either at the Q209 position of exon 5 or, less frequently, at the R183 position in exon 4. These mutations, while common in uveal melanoma, are not prognostically relevant.</p><p></p><p class="bulletIndent1">The oncogenic potential of these mutations and their ability to activate the MAPK pathway through the upregulation of protein kinase C (PKC) has been confirmed in murine models. Additionally, the potential importance of this pathway in patients with uveal melanoma was illustrated by a series of 187 patients with uveal melanocytic tumors [<a href="#rid32">32</a>]. Somatic mutations were identified in approximately 80 percent of cases. In 139 blue nevi, a cutaneous lesion associated with uveal melanoma, mutations were present in over 60 percent of cases. Of potential importance, <em>GNAQ</em> mutations were proportionally more common in blue nevi and primary uveal melanomas, while <em>GNA11</em> mutations predominated in metastatic uveal melanoma deposits.</p><p></p><p class="bulletIndent1">By contrast, these somatic mutations in <em>GNAQ</em> and <em>GNA11</em> were absent in all nine cases of conjunctival melanoma, and a somatic mutation in these genes was identified in only 1 of 273 cases of extraocular melanoma (0.4 percent).</p><p></p><p class="bulletIndent1">Additional studies on agents targeting the MAPK pathway in uveal melanoma are discussed separately. (See  <a class="medical medical_review" href="/d/html/113047.html" rel="external">"Metastatic uveal melanoma", section on 'Molecularly targeted agents'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>PLCB4</em></strong><strong> and </strong><strong><em>CYSLTR2</em></strong> – Most of the remaining tumors without mutations in <em>GNAQ</em> and <em>GNA11</em> harbor mutations in other members of Gaq signaling pathway, including the<em> </em>downstream effector of Gaq signaling <em>PLCB4</em> [<a href="#rid60">60</a>]<em>,</em> and the G protein coupled receptor <em>CYSLTR2</em> [<a href="#rid61">61</a>]. Mutations in <em>PLCB4</em> and <em>CYSLTR2</em> are also mutually exclusive of those in <em>GNAQ</em> and <em>GNA11</em> [<a href="#rid62">62</a>]. These mutations are also not prognostically relevant.</p><p></p><p class="bulletIndent1">A recurrent hotspot mutation of <em>CYSLTR2</em> at position 129, a substitution of leucine for glutamine, is associated with gain of function of the G-protein coupled receptor [<a href="#rid61">61</a>]. Mutations in <em>CYSLTR2</em> are present <strong>in 3 to 4 percent</strong> of uveal melanomas [<a href="#rid61">61,62</a>] and are mutually exclusive of <em>GNAQ </em>and<em> GNA11</em> mutations. </p><p></p><p class="bulletIndent1">Together, mutations in either a G-protein coupled receptor or the alpha-subunits of a G-protein coupled receptor occur in over 96 percent of patients [<a href="#rid62">62</a>]. </p><p></p><p class="headingAnchor" id="H3109289478"><span class="h4">Mutations with prognostic relevance</span><span class="headingEndMark"> — </span>Mutually exclusive "progression mutations" in <em>BAP1</em>, <em>SF3B1</em>, and <em>EIF1AX</em> appear to have prognostic significance. These mutations are used to determine the post-treatment surveillance of patients with primary uveal melanoma. (See  <a class="medical medical_review" href="/d/html/7617.html" rel="external">"Initial management of uveal and conjunctival melanomas", section on 'Posttreatment systemic surveillance'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>BAP1</em></strong> – The <em>BAP1</em> gene is a nuclear deubiquitinase located on chromosome 3p21.1 that functions as a tumor suppressor through multiple incompletely understood mechanisms [<a href="#rid63">63</a>]. Mutations in the <em>BAP1</em> gene are identified <strong>in almost half </strong>of primary uveal melanomas and are associated with the highest risk of metastatic disease. </p><p></p><p class="bulletIndent1">Inactivating mutations in <em>BAP1</em>, associated with loss of the other allele through whole chromosome 3 loss, were initially identified in up to 50 percent of primary uveal melanomas and in the vast majority of metastasizing class 2 uveal melanomas (including one patient with a germline <em>BAP1</em> mutation) [<a href="#rid32">32</a>]. Subsequent population-based studies have indicated that about 2 to 3 percent of all patients with uveal melanoma harbor germline <em>BAP1</em> mutations [<a href="#rid31">31,53</a>].</p><p></p><p class="bulletIndent1">Monosomy of chromosome 3 has been associated with the development of metastatic disease in patients with uveal melanoma but is rare in patients with cutaneous melanoma [<a href="#rid64">64-69</a>]. As an example, genetic analysis of fine needle aspirates found that partial or complete monosomy of chromosome 3 was present in 27 and 25 percent of cases in a series of 500 uveal melanomas [<a href="#rid69">69</a>]. The presence of complete monosomy was associated with significantly poorer survival at three years.</p><p></p><p class="bulletIndent1">Somatic mutations in the gene encoding BAP1 on chromosome 3 have been identified in 26 of 31 uveal melanomas (84 percent), with a gene expression profile consistent with a high metastatic risk (greater than 80 percent at five years) [<a href="#rid33">33</a>]. By contrast, mutations in <em>BAP1</em> were present in only 1 of 26 patients (4 percent) classified as being at low risk for metastases. Loss of function of this tumor suppressor gene is thought to result from the combination of a somatic mutation in one allele and the loss of one chromosome 3 allele.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>SF3B1</em></strong><strong> and </strong><strong><em>EIF1AX</em></strong> – Mutations in <em>SF3B1</em> and in <em>EIF1AX</em> are associated with a more favorable prognosis and late onset of metastasis. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong><em>SF3B1</em></strong><em> </em>– <em>SF3B1</em> encodes the splicing factor 3B subunit 1, which is involved in pre-messenger-RNA splicing. Change-of-function point mutations occurring mostly at codon 625 are present in approximately <strong>19 to 30 percent </strong>of primary uveal melanomas [<a href="#rid52">52,54-58</a>] and were associated with splicing defects that contribute to tumor progression by poorly understood mechanisms [<a href="#rid60">60,61</a>]. <em>SF3B1</em> mutations are mostly mutually exclusive with <em>BAP1</em> mutations and are associated with a lower rate and later median onset of metastatic disease [<a href="#rid33">33,70</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong><em>EIF1AX</em></strong> – <em>EIF1AX</em> encodes the X-linked eukaryotic translation initiation factor 1A, which stimulates transfer of methionine transfer RNA to the small ribosomal subunit. Somatic mutations in <em>EIF1AX</em> occur in approximately <strong>15 to 24 percent </strong>of primary uveal melanomas, and mostly mutually exclusive with <em>BAP1</em> and <em>SF3B1</em> mutations [<a href="#rid33">33,52,58</a>]. Uveal melanomas containing mutations in <em>EIF1AX</em>, but not in <em>BAP1</em> or <em>SF3B1</em>, are associated with the best prognosis among uveal melanoma prognostic subgroups [<a href="#rid33">33</a>]. Most mutations in <em>EIF1AX</em> involve small, in-frame alterations affecting the N terminus of the protein that function in tumorigenesis by poorly understood mechanisms [<a href="#rid55">55</a>].</p><p></p><p class="bulletIndent1"><em>SF3B1</em>, <em>EIF1AX</em>, and <em>BAP1</em> mutations are almost mutually exclusive, indicating alternative molecular pathways leading to distinct clinical outcomes. For example, in one study, when compared with wild type, <em>SF3B1 </em>mutation was associated with a lower rate of progression to metastases (progression-free survival of approximately 80 percent at five years) [<a href="#rid58">58</a>]. It is not known how much of this improvement is due to the presence of these mutations versus the absence of the <em>BAP1</em> mutation. Further studies are required to validate the positive prognosis associated with <em>SF3B1</em> and <em>EIF1AX</em> mutations. </p><p></p><p class="headingAnchor" id="H1095521349"><span class="h3">Conjunctival melanoma</span><span class="headingEndMark"> — </span>Unlike uveal melanoma, conjunctival melanoma is associated with activation of the MAPK pathway, with mutations present in either <em>BRAF</em> or <em>NRAS</em> in approximately one-half of cases [<a href="#rid71">71</a>]. The ultraviolet (UV) signature displayed by many conjunctival melanomas suggests they may have more in common with intermittently sun-exposed cutaneous melanomas than with uveal or mucosal melanomas.</p><p class="headingAnchor" id="H220235"><span class="h3">Acral and mucosal melanoma</span><span class="headingEndMark"> — </span>In mucosal and acral melanomas, <em>KIT</em> is the most frequently mutated gene (15 to 40 percent of cases). <em>BRAF</em> and <em>NRAS</em> mutations are much less common, occurring in less than 10 percent of cases overall. <a class="drug drug_general" data-topicid="8961" href="/d/drug information/8961.html" rel="external">Imatinib</a>, an inhibitor of kit, a cell surface receptor that can activate RAS, has demonstrated activity in this population. (See  <a class="medical medical_review" href="/d/html/138441.html" rel="external">"Treatment of metastatic mucosal melanoma", section on 'KIT mutation'</a>.)</p><p class="headingAnchor" id="H5643606"><span class="h2">Mutation status and prognosis</span><span class="headingEndMark"> — </span>The prognosis of patients with advanced melanoma is influenced by the specific mutations present in a specific tumor. </p><p class="bulletIndent1"><span class="glyph">●</span>Melanomas with somatic mutations of either <em>NRAS</em> or <em>BRAF</em> are associated with a poorer prognosis. However, patients whose tumors contain <em>BRAF</em> mutations have improved response rates and survival when treated with BRAF plus MEK inhibitors. (See  <a class="medical medical_review" href="/d/html/7618.html" rel="external">"Tumor, node, metastasis (TNM) staging system and other prognostic factors in cutaneous melanoma", section on 'Mutation status'</a> and  <a class="medical medical_review" href="/d/html/15408.html" rel="external">"Systemic treatment of metastatic melanoma with BRAF and other molecular alterations", section on 'Dabrafenib plus trametinib'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with acral or mucosal melanoma that contain <em>KIT</em> mutations have a poorer prognosis compared with similar patients whose tumors do not contain identifiable <em>KIT</em> mutations, although they have improved response rates and survival when treated with <a class="drug drug_general" data-topicid="8961" href="/d/drug information/8961.html" rel="external">imatinib</a> or other KIT inhibitors. (See  <a class="medical medical_review" href="/d/html/16904.html" rel="external">"Locoregional mucosal melanoma: Epidemiology, clinical diagnosis, and treatment"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with ocular melanoma, somatic mutations in either <em>GNAQ</em> or <em>GNA11</em> do not appear to be associated with poor prognosis (at least relative to the small group of patients with tumors lacking either mutation). Mutation in the <em>BAP1</em> gene, which is thought to regulate cellular growth control via as yet incompletely understood mechanisms, does appear to be associated with increased risk of metastasis and worsened prognosis. (See <a class="local">'Uveal melanomas'</a> above and  <a class="medical medical_review" href="/d/html/7617.html" rel="external">"Initial management of uveal and conjunctival melanomas", section on 'Posttreatment systemic surveillance'</a>.)</p><p></p><p class="headingAnchor" id="H220317"><span class="h1">ROLE OF MITF</span><span class="headingEndMark"> — </span>Microphthalmia-associated transcription factor (MITF) is crucial to melanin production. (See <a class="local">'Melanocyte biology'</a> above.)</p><p>MITF also has important roles in cell cycling during melanocyte differentiation, melanocyte invasion during physiologic migration, and the promotion of melanocyte survival [<a href="#rid72">72</a>]. While these functions are critical to normal melanocyte biology, MITF dysregulation can contribute to the pathogenesis of melanoma [<a href="#rid73">73</a>]. </p><p>MITF amplification occurs in approximately 20 percent of melanomas and appears to be associated with poorer survival [<a href="#rid73">73,74</a>]. Additionally, a specific germline mutation in MITF has been associated with increased nevus count, non-blue eye color, and elevated melanoma risk [<a href="#rid75">75,76</a>].</p><p>Mechanistic data have revealed an intriguing relationship between MITF and the mitogen-activated protein kinase (MAPK) pathway, which is relevant to therapies targeting BRAF. MITF serves as a direct substrate for phosphorylation at serine 73 by MAPK [<a href="#rid77">77</a>]. One of the critical sequelae of this phosphorylation is the targeting of MITF for ubiquitin modification, resulting in rapid degradation of MITF protein [<a href="#rid78">78</a>]. A key consequence of this homeostatic circuitry is that BRAF antagonists block MITF phosphorylation, ubiquitination, and degradation, resulting in its stabilization and profound upregulation of certain (if not all) MITF transcriptional target genes. Some of these target genes are known antigens in immunologic recognition of melanomas, such as Mart1 or gp100. Thus, BRAF antagonism may enhance the antigenicity of melanomas via enhanced MITF stability and subsequent upregulation of melanocytic antigen expression [<a href="#rid79">79</a>]. Additionally, MITF was shown to directly control expression of PGC1a, which induces mitochondrial respiration and an attendant metabolic shift from glycolysis to oxidative phosphorylation [<a href="#rid80">80</a>].</p><p class="headingAnchor" id="H5643613"><span class="h1">CLINICAL IMPLICATIONS</span><span class="headingEndMark"> — </span>Small molecule inhibitors have been developed that effectively target BRAF monomers, MEK, and KIT mutations in patients with melanoma. Inhibitors of BRAF homo- and heterodimers as well as mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) are under development</p><p class="headingAnchor" id="H5643627"><span class="h2">BRAF inhibitors</span><span class="headingEndMark"> — </span>Potent selective inhibitors of BRAF monomers, such as <a class="drug drug_general" data-topicid="16798" href="/d/drug information/16798.html" rel="external">vemurafenib</a>, <a class="drug drug_general" data-topicid="118325" href="/d/drug information/118325.html" rel="external">encorafenib</a>, and <a class="drug drug_general" data-topicid="89686" href="/d/drug information/89686.html" rel="external">dabrafenib</a>, have induced tumor regression and prolonged overall survival in patients with metastatic melanoma that contains the mutated form of <em>BRAF</em> V600E. In such patients, these agents are administered in combination with MEK inhibitors. (See  <a class="medical medical_review" href="/d/html/15408.html" rel="external">"Systemic treatment of metastatic melanoma with BRAF and other molecular alterations", section on 'BRAF V600 mutant disease'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mechanisms of action</strong> –<strong> </strong>Treatment with BRAF inhibitors leads to a reduction in levels of phosphoextracellular responsive kinase (pERK) in tumors containing the <em>BRAF</em> V600E mutation, which is associated with clinical response [<a href="#rid81">81,82</a>].<strong> </strong>However, selective BRAF inhibitors may paradoxically hyperstimulate RAF kinases within cells in which the RAS pathway is activated upstream of a wild-type BRAF kinase [<a href="#rid83">83-85</a>]. The addition of an MEK inhibitor to a BRAF inhibitor blocks this paradoxical activation of the MAPK pathway.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mechanisms of resistance</strong> –<strong> </strong>Virtually every patient treated with an inhibitor of BRAF as monotherapy eventually has disease progression [<a href="#rid86">86</a>]. No consistent mechanism of resistance has been identified.</p><p></p><p class="bulletIndent1">Resistance has not been associated with the development of a second mutation that impairs the binding of the treatment drug to BRAF, a resistance mechanism observed in targeted therapy in other malignancies. Several resistance mechanisms have been described that typically involve tumor cell reactivation via the MAPK pathway through a variety of alternative means.</p><p></p><p class="bulletIndent1">Studies using <em>BRAF</em> V600E mutated cells that were generated to exhibit acquired resistance to BRAF inhibitors provide insights into how <em>BRAF</em> mutated cells survive BRAF inhibition. Several mechanisms of resistance have been identified, each of which has been investigated in at least a small number of tumor cells:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Bypass mechanisms within the MAPK pathway can restore ERK activation, regardless of ongoing BRAF inhibition. Reestablishment of signaling can be achieved through upregulation of receptor tyrosine kinases (ie, platelet-derived growth factor receptor beta [PDGFRB], human epidermal growth factor 2 [HER2]) [<a href="#rid87">87,88</a>], activation of NRAS via mutation [<a href="#rid88">88-90</a>], upregulation of CRAF [<a href="#rid87">87,91</a>], activating mutations of MEK [<a href="#rid90">90,92,93</a>], activation of the serine/threonine MAPK kinases (COT) [<a href="#rid87">87</a>], overexpression of mutant BRAF [<a href="#rid94">94</a>], and loss of NF1 [<a href="#rid95">95</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Shortened forms of the BRAF protein may be produced due to altered RNA processing [<a href="#rid96">96</a>]. These modified forms of the BRAF protein can activate the MAPK pathway even in the presence of a BRAF inhibitor. This abnormality was identified in 6 of 19 patients with acquired resistance to <a class="drug drug_general" data-topicid="16798" href="/d/drug information/16798.html" rel="external">vemurafenib</a>.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Signaling through the parallel growth and survival PI3K pathway, which can be initiated by insulin growth factor receptor 1 (IGF-1R) expression or <em>AKT1</em> mutation, is an alternative mechanism of acquired resistance that has been described and fits the definition of an outside-of-pathway bypass mechanism [<a href="#rid97">97,98</a>].</p><p></p><p class="bulletIndent1">While complete primary resistance to BRAF inhibition (ie, active progression during initiation of therapy) is seen in less than 10 percent of patients with <em>BRAF</em> mutant melanoma treated with <a class="drug drug_general" data-topicid="16798" href="/d/drug information/16798.html" rel="external">vemurafenib</a> [<a href="#rid99">99</a>], only a small fraction of patients experience complete remissions, suggesting the existence of mechanism(s) that acutely limit the tumor lethality of BRAF inhibition in most patients.</p><p></p><p class="bulletIndent1">Preclinical studies suggest that elevated pretreatment levels of CRAF as well as baseline CCND1 amplification in tumors, leading to downstream overexpression of cyclin D1 and enhanced CDK4 expression, are pretreatment biomarkers worth further investigation [<a href="#rid91">91,100</a>]. In evaluation of baseline samples obtained from patients with <em>BRAF</em> mutant melanoma prior to treatment with <a class="drug drug_general" data-topicid="89686" href="/d/drug information/89686.html" rel="external">dabrafenib</a>, loss of the cyclin-dependent kinase inhibitor CDKN2A (p16<sup>INK4a</sup>) and amplification of CCND1 were associated with poorer outcome to therapy [<a href="#rid101">101</a>]. Additionally, high pretreatment expression of the anti-apoptotic BCL-2 family member BCL2A1, as well as elevated stromal and plasma hepatocyte growth factor, and loss of phosphatase and tensin homolog (PTEN) expression are associated with poorer outcomes to BRAF inhibitor therapy [<a href="#rid101">101-104</a>]. Finally, contemporary studies have identified a metabolic pathway through which BRAF inhibition upregulates mitochondrial respiration via MITF and PGC1a in a response that limits the ability of BRAF inhibition to kill melanoma cells [<a href="#rid80">80</a>].</p><p></p><p class="headingAnchor" id="H216686"><span class="h2">MEK inhibitors</span><span class="headingEndMark"> — </span>MEK is a downstream mediator of RAS and RAF activation in the MAPK pathway. Although the MAPK pathway is activated in most melanomas, the presence of <em>BRAF</em> V600E mutation correlates strongly with response to MEK inhibition in murine melanoma xenograft models [<a href="#rid105">105</a>]. </p><p>Various MEK inhibitors (eg, <a class="drug drug_general" data-topicid="89685" href="/d/drug information/89685.html" rel="external">trametinib</a>, <a class="drug drug_general" data-topicid="105354" href="/d/drug information/105354.html" rel="external">cobimetinib</a>, <a class="drug drug_general" data-topicid="118324" href="/d/drug information/118324.html" rel="external">binimetinib</a>, and <a class="drug drug_general" data-topicid="127843" href="/d/drug information/127843.html" rel="external">selumetinib</a>) have clinical evidence of activity, particularly in patients with characteristic <em>BRAF</em> mutations. MEK inhibitors are administered in combination with BRAF inhibitors in patients with metastatic melanoma and a targetable <em>BRAF</em> mutation. (See <a class="local">'BRAF plus MEK inhibitors'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Trametinib</strong> –<strong> </strong><a class="drug drug_general" data-topicid="89685" href="/d/drug information/89685.html" rel="external">Trametinib</a> (either as a single agent or in combination with the BRAF inhibitor <a class="drug drug_general" data-topicid="89686" href="/d/drug information/89686.html" rel="external">dabrafenib</a>) prolongs survival in patients with tumors harboring <em>BRAF</em> V600 mutations. In addition, trametinib is possibly useful in patients with <em>NRAS</em> and <em>GNAQ</em>/<em>GNA11</em> mutations. (See  <a class="medical medical_review" href="/d/html/15408.html" rel="external">"Systemic treatment of metastatic melanoma with BRAF and other molecular alterations", section on 'Dabrafenib plus trametinib'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cobimetinib</strong> –<strong> </strong>The activity of <a class="drug drug_general" data-topicid="105354" href="/d/drug information/105354.html" rel="external">cobimetinib</a> (in combination with the BRAF inhibitor <a class="drug drug_general" data-topicid="16798" href="/d/drug information/16798.html" rel="external">vemurafenib</a>) in patients with metastatic melanoma is discussed separately. (See  <a class="medical medical_review" href="/d/html/15408.html" rel="external">"Systemic treatment of metastatic melanoma with BRAF and other molecular alterations", section on 'Vemurafenib plus cobimetinib'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Binimetinib</strong> –<strong> </strong><a class="drug drug_general" data-topicid="118324" href="/d/drug information/118324.html" rel="external">Binimetinib</a> has clinical efficacy in combination with <a class="drug drug_general" data-topicid="118325" href="/d/drug information/118325.html" rel="external">encorafenib</a> in patients with <em>BRAF </em>V600E mutations and as a single agent in patients with <em>NRAS</em> mutations. These data are discussed separately. (See  <a class="medical medical_review" href="/d/html/15408.html" rel="external">"Systemic treatment of metastatic melanoma with BRAF and other molecular alterations", section on 'Encorafenib plus binimetinib'</a> and  <a class="medical medical_review" href="/d/html/15408.html" rel="external">"Systemic treatment of metastatic melanoma with BRAF and other molecular alterations", section on 'NRAS mutation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Selumetinib</strong> –<strong> </strong><a class="drug drug_general" data-topicid="127843" href="/d/drug information/127843.html" rel="external">Selumetinib</a> in combination with chemotherapy (<a class="drug drug_general" data-topicid="9699" href="/d/drug information/9699.html" rel="external">temozolomide</a> or <a class="drug drug_general" data-topicid="9316" href="/d/drug information/9316.html" rel="external">dacarbazine</a>) has limited efficacy in patients with uveal melanoma. These data are discussed separately. (See  <a class="medical medical_review" href="/d/html/113047.html" rel="external">"Metastatic uveal melanoma", section on 'Molecularly targeted agents'</a>.)</p><p></p><p class="headingAnchor" id="H2801330156"><span class="h2">BRAF plus MEK inhibitors</span><span class="headingEndMark"> — </span>The combination of BRAF plus MEK inhibitors (eg, <a class="drug drug_general" data-topicid="89686" href="/d/drug information/89686.html" rel="external">dabrafenib</a> plus <a class="drug drug_general" data-topicid="89685" href="/d/drug information/89685.html" rel="external">trametinib</a>, <a class="drug drug_general" data-topicid="16798" href="/d/drug information/16798.html" rel="external">vemurafenib</a> plus <a class="drug drug_general" data-topicid="105354" href="/d/drug information/105354.html" rel="external">cobimetinib</a>, <a class="drug drug_general" data-topicid="118325" href="/d/drug information/118325.html" rel="external">encorafenib</a> plus <a class="drug drug_general" data-topicid="118324" href="/d/drug information/118324.html" rel="external">binimetinib</a>) is safe and effective in patients with <em>BRAF</em> V600 mutant melanoma. The clinical trial data supporting these combinations are discussed separately. (See  <a class="medical medical_review" href="/d/html/15408.html" rel="external">"Systemic treatment of metastatic melanoma with BRAF and other molecular alterations", section on 'Choice of BRAF plus MEK inhibitor therapy'</a>.)</p><p class="headingAnchor" id="H1210222958"><span class="h2">KIT inhibitors</span><span class="headingEndMark"> — </span>Activating mutations of <em>KIT</em> have been demonstrated in only a small percentage of all melanoma cases. KIT inhibitors have demonstrated encouraging activity in highly selected populations of patients with melanoma. These data are discussed separately. (See  <a class="medical medical_review" href="/d/html/15408.html" rel="external">"Systemic treatment of metastatic melanoma with BRAF and other molecular alterations", section on 'KIT mutations (acral and mucosal melanoma)'</a>.)</p><p class="headingAnchor" id="H1037466816"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/15499.html" rel="external">"Patient education: Melanoma skin cancer (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/889.html" rel="external">"Patient education: Melanoma treatment; localized melanoma (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/892.html" rel="external">"Patient education: Melanoma treatment; advanced or metastatic melanoma (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H378439991"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/118501.html" rel="external">"Society guideline links: Melanoma screening, prevention, diagnosis, and management"</a>.)</p><p class="headingAnchor" id="H5643648"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathways associated with melanoma</strong> – Research into the molecular pathogenesis of melanoma has identified the mitogen-activated protein kinase (MAPK) pathway  (<a class="graphic graphic_figure graphicRef53134" href="/d/graphic/53134.html" rel="external">figure 1</a>) and microphthalmia-associated transcription factor (MITF) as key factors in the development of melanoma. (See <a class="local">'MAPK pathway'</a> above and <a class="local">'Role of MITF'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Common mutations</strong> – Although the MAPK pathway is activated in almost all melanomas, different abnormalities in the pathway are associated with specific subtypes of melanoma. (See <a class="local">'Molecular characterization of melanocytic lesions'</a> above.)</p><p></p><p class="bulletIndent1">The most common alterations include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><em>BRAF</em> and <em>NRAS</em> in cutaneous and conjunctival melanomas. (See <a class="local">'Cutaneous melanoma and precursor lesions'</a> above and <a class="local">'Classification of BRAF mutations'</a> above and <a class="local">'Conjunctival melanoma'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><em>KIT</em> in acral and mucosal melanomas. (See <a class="local">'Acral and mucosal melanoma'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><em>GNAQ</em> and <em>GNA11 </em>(among others) in uveal melanomas. Other mutations such as <em>BAP1</em>, <em>SF3B1</em>, and <em>EIF1AX</em> have prognostic significance and are used to determine posttreatment surveillance. (See <a class="local">'Uveal melanomas'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical significance</strong> – Understanding of the importance of the MAPK pathway and <em>BRAF</em> mutations has led to the development of combination BRAF/MEK inhibitors, which significantly prolong survival in patients with metastatic melanoma containing a <em>BRAF</em> V600 mutation. (See <a class="local">'Clinical implications'</a> above and  <a class="medical medical_review" href="/d/html/15408.html" rel="external">"Systemic treatment of metastatic melanoma with BRAF and other molecular alterations"</a>.)</p><p></p><p class="headingAnchor" id="H4241117978"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges David E Fisher, MD, PhD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin 2023; 73:17.</a></li><li class="breakAll">Global Cancer Observatory. International Agency for Research on Cancer. World Health Organization. Available at: https://gco.iarc.fr/ (Accessed on December 13, 2023).</li><li><a class="nounderline abstract_t">Chin L, Garraway LA, Fisher DE. Malignant melanoma: genetics and therapeutics in the genomic era. Genes Dev 2006; 20:2149.</a></li><li><a class="nounderline abstract_t">Lin JY, Fisher DE. Melanocyte biology and skin pigmentation. Nature 2007; 445:843.</a></li><li><a class="nounderline abstract_t">Rees JL. Genetics of hair and skin color. Annu Rev Genet 2003; 37:67.</a></li><li><a class="nounderline abstract_t">Cui R, Widlund HR, Feige E, et al. Central role of p53 in the suntan response and pathologic hyperpigmentation. Cell 2007; 128:853.</a></li><li><a class="nounderline abstract_t">Fisher DE, James WD. Indoor tanning--science, behavior, and policy. N Engl J Med 2010; 363:901.</a></li><li><a class="nounderline abstract_t">Khaled M, Levy C, Fisher DE. Control of melanocyte differentiation by a MITF-PDE4D3 homeostatic circuit. Genes Dev 2010; 24:2276.</a></li><li><a class="nounderline abstract_t">D'Orazio JA, Nobuhisa T, Cui R, et al. Topical drug rescue strategy and skin protection based on the role of Mc1r in UV-induced tanning. Nature 2006; 443:340.</a></li><li><a class="nounderline abstract_t">Omholt K, Platz A, Kanter L, et al. NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clin Cancer Res 2003; 9:6483.</a></li><li><a class="nounderline abstract_t">Krauthammer M, Kong Y, Bacchiocchi A, et al. Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas. Nat Genet 2015; 47:996.</a></li><li><a class="nounderline abstract_t">Cancer Genome Atlas Network. Genomic Classification of Cutaneous Melanoma. Cell 2015; 161:1681.</a></li><li><a class="nounderline abstract_t">Bardeesy N, Kim M, Xu J, et al. Role of epidermal growth factor receptor signaling in RAS-driven melanoma. Mol Cell Biol 2005; 25:4176.</a></li><li><a class="nounderline abstract_t">Furge KA, Kiewlich D, Le P, et al. Suppression of Ras-mediated tumorigenicity and metastasis through inhibition of the Met receptor tyrosine kinase. Proc Natl Acad Sci U S A 2001; 98:10722.</a></li><li><a class="nounderline abstract_t">Monsel G, Ortonne N, Bagot M, et al. c-Kit mutants require hypoxia-inducible factor 1alpha to transform melanocytes. Oncogene 2010; 29:227.</a></li><li><a class="nounderline abstract_t">Maertens O, Johnson B, Hollstein P, et al. Elucidating distinct roles for NF1 in melanomagenesis. Cancer Discov 2013; 3:338.</a></li><li><a class="nounderline abstract_t">Beeram M, Patnaik A, Rowinsky EK. Raf: a strategic target for therapeutic development against cancer. J Clin Oncol 2005; 23:6771.</a></li><li><a class="nounderline abstract_t">Chong H, Guan KL. Regulation of Raf through phosphorylation and N terminus-C terminus interaction. J Biol Chem 2003; 278:36269.</a></li><li><a class="nounderline abstract_t">Fischer A, Hekman M, Kuhlmann J, et al. B- and C-RAF display essential differences in their binding to Ras: the isotype-specific N terminus of B-RAF facilitates Ras binding. J Biol Chem 2007; 282:26503.</a></li><li><a class="nounderline abstract_t">Tran NH, Wu X, Frost JA. B-Raf and Raf-1 are regulated by distinct autoregulatory mechanisms. J Biol Chem 2005; 280:16244.</a></li><li><a class="nounderline abstract_t">Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417:949.</a></li><li><a class="nounderline abstract_t">Garnett MJ, Rana S, Paterson H, et al. Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization. Mol Cell 2005; 20:963.</a></li><li><a class="nounderline abstract_t">Terai K, Matsuda M. The amino-terminal B-Raf-specific region mediates calcium-dependent homo- and hetero-dimerization of Raf. EMBO J 2006; 25:3556.</a></li><li><a class="nounderline abstract_t">Pollock PM, Harper UL, Hansen KS, et al. High frequency of BRAF mutations in nevi. Nat Genet 2003; 33:19.</a></li><li><a class="nounderline abstract_t">Dong J, Phelps RG, Qiao R, et al. BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma. Cancer Res 2003; 63:3883.</a></li><li><a class="nounderline abstract_t">Poynter JN, Elder JT, Fullen DR, et al. BRAF and NRAS mutations in melanoma and melanocytic nevi. Melanoma Res 2006; 16:267.</a></li><li><a class="nounderline abstract_t">Lin J, Goto Y, Murata H, et al. Polyclonality of BRAF mutations in primary melanoma and the selection of mutant alleles during progression. Br J Cancer 2011; 104:464.</a></li><li><a class="nounderline abstract_t">Lin J, Takata M, Murata H, et al. Polyclonality of BRAF mutations in acquired melanocytic nevi. J Natl Cancer Inst 2009; 101:1423.</a></li><li><a class="nounderline abstract_t">Sharma A, Trivedi NR, Zimmerman MA, et al. Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Res 2005; 65:2412.</a></li><li><a class="nounderline abstract_t">Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005; 353:2135.</a></li><li><a class="nounderline abstract_t">Van Raamsdonk CD, Bezrookove V, Green G, et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 2009; 457:599.</a></li><li><a class="nounderline abstract_t">Van Raamsdonk CD, Griewank KG, Crosby MB, et al. Mutations in GNA11 in uveal melanoma. N Engl J Med 2010; 363:2191.</a></li><li><a class="nounderline abstract_t">Harbour JW, Onken MD, Roberson ED, et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 2010; 330:1410.</a></li><li><a class="nounderline abstract_t">Kong Y, Si L, Zhu Y, et al. Large-scale analysis of KIT aberrations in Chinese patients with melanoma. Clin Cancer Res 2011; 17:1684.</a></li><li><a class="nounderline abstract_t">Carvajal RD, Antonescu CR, Wolchok JD, et al. KIT as a therapeutic target in metastatic melanoma. JAMA 2011; 305:2327.</a></li><li><a class="nounderline abstract_t">Guo J, Si L, Kong Y, et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol 2011; 29:2904.</a></li><li><a class="nounderline abstract_t">Curtin JA, Busam K, Pinkel D, Bastian BC. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006; 24:4340.</a></li><li><a class="nounderline abstract_t">Beadling C, Jacobson-Dunlop E, Hodi FS, et al. KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res 2008; 14:6821.</a></li><li><a class="nounderline abstract_t">Albino AP, Le Strange R, Oliff AI, et al. Transforming ras genes from human melanoma: a manifestation of tumour heterogeneity? Nature 1984; 308:69.</a></li><li><a class="nounderline abstract_t">Ball NJ, Yohn JJ, Morelli JG, et al. Ras mutations in human melanoma: a marker of malignant progression. J Invest Dermatol 1994; 102:285.</a></li><li><a class="nounderline abstract_t">Platz A, Ringborg U, Brahme EM, Lagerlöf B. Melanoma metastases from patients with hereditary cutaneous malignant melanoma contain a high frequency of N-ras activating mutations. Melanoma Res 1994; 4:169.</a></li><li><a class="nounderline abstract_t">van 't Veer LJ, Burgering BM, Versteeg R, et al. N-ras mutations in human cutaneous melanoma from sun-exposed body sites. Mol Cell Biol 1989; 9:3114.</a></li><li><a class="nounderline abstract_t">Jin SA, Chun SM, Choi YD, et al. BRAF mutations and KIT aberrations and their clinicopathological correlation in 202 Korean melanomas. J Invest Dermatol 2013; 133:579.</a></li><li><a class="nounderline abstract_t">Lin YC, Chang YM, Ho JY, et al. C-kit expression of melanocytic neoplasm and association with clinicopathological parameters and anatomic locations in Chinese people. Am J Dermatopathol 2013; 35:569.</a></li><li><a class="nounderline abstract_t">Hodis E, Watson IR, Kryukov GV, et al. A landscape of driver mutations in melanoma. Cell 2012; 150:251.</a></li><li><a class="nounderline abstract_t">Menzies AM, Haydu LE, Visintin L, et al. Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma. Clin Cancer Res 2012; 18:3242.</a></li><li><a class="nounderline abstract_t">Long GV, Menzies AM, Nagrial AM, et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 2011; 29:1239.</a></li><li><a class="nounderline abstract_t">Shain AH, Yeh I, Kovalyshyn I, et al. The Genetic Evolution of Melanoma from Precursor Lesions. N Engl J Med 2015; 373:1926.</a></li><li><a class="nounderline abstract_t">Shoushtari AN, Chatila WK, Arora A, et al. Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas. Clin Cancer Res 2021; 27:2226.</a></li><li><a class="nounderline abstract_t">Yao Z, Torres NM, Tao A, et al. BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition. Cancer Cell 2015; 28:370.</a></li><li><a class="nounderline abstract_t">Yao Z, Yaeger R, Rodrik-Outmezguine VS, et al. Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS. Nature 2017; 548:234.</a></li><li><a class="nounderline abstract_t">Furney SJ, Pedersen M, Gentien D, et al. SF3B1 mutations are associated with alternative splicing in uveal melanoma. Cancer Discov 2013; 3:1122.</a></li><li><a class="nounderline abstract_t">Onken MD, Worley LA, Long MD, et al. Oncogenic mutations in GNAQ occur early in uveal melanoma. Invest Ophthalmol Vis Sci 2008; 49:5230.</a></li><li><a class="nounderline abstract_t">Shoushtari AN, Carvajal RD. GNAQ and GNA11 mutations in uveal melanoma. Melanoma Res 2014; 24:525.</a></li><li><a class="nounderline abstract_t">Feng X, Degese MS, Iglesias-Bartolome R, et al. Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry. Cancer Cell 2014; 25:831.</a></li><li><a class="nounderline abstract_t">Field MG, Harbour JW. Recent developments in prognostic and predictive testing in uveal melanoma. Curr Opin Ophthalmol 2014; 25:234.</a></li><li><a class="nounderline abstract_t">Sarubi HC, Pereira NB, Gomes CC, et al. Molecular and immunohistochemical analyses of uveal melanoma patient cohort. Melanoma Res 2019; 29:248.</a></li><li><a class="nounderline abstract_t">Harbour JW, Roberson ED, Anbunathan H, et al. Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma. Nat Genet 2013; 45:133.</a></li><li><a class="nounderline abstract_t">Yavuzyigitoglu S, Koopmans AE, Verdijk RM, et al. Uveal Melanomas with SF3B1 Mutations: A Distinct Subclass Associated with Late-Onset Metastases. Ophthalmology 2016; 123:1118.</a></li><li><a class="nounderline abstract_t">Johansson P, Aoude LG, Wadt K, et al. Deep sequencing of uveal melanoma identifies a recurrent mutation in PLCB4. Oncotarget 2016; 7:4624.</a></li><li><a class="nounderline abstract_t">Moore AR, Ceraudo E, Sher JJ, et al. Recurrent activating mutations of G-protein-coupled receptor CYSLTR2 in uveal melanoma. Nat Genet 2016; 48:675.</a></li><li><a class="nounderline abstract_t">Robertson AG, Shih J, Yau C, et al. Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma. Cancer Cell 2017; 32:204.</a></li><li class="breakAll">Peperno-Neumann S, Kapiteijin E, Larkin JM, et al. Landscape of genetic alterations in patients with metastatic uveal melanoma (abstract) 2014 American Society of Clinical Oncology meeting.</li><li><a class="nounderline abstract_t">Prescher G, Bornfeld N, Hirche H, et al. Prognostic implications of monosomy 3 in uveal melanoma. Lancet 1996; 347:1222.</a></li><li><a class="nounderline abstract_t">Desjardins L, Levy-Gabriel C, Lumbroso-Lerouic L, et al. [Prognostic factors for malignant uveal melanoma. Retrospective study on 2,241 patients and recent contribution of monosomy-3 research]. J Fr Ophtalmol 2006; 29:741.</a></li><li><a class="nounderline abstract_t">Sisley K, Rennie IG, Parsons MA, et al. Abnormalities of chromosomes 3 and 8 in posterior uveal melanoma correlate with prognosis. Genes Chromosomes Cancer 1997; 19:22.</a></li><li><a class="nounderline abstract_t">Becher R, Korn WM, Prescher G. Use of fluorescence in situ hybridization and comparative genomic hybridization in the cytogenetic analysis of testicular germ cell tumors and uveal melanomas. Cancer Genet Cytogenet 1997; 93:22.</a></li><li><a class="nounderline abstract_t">Parrella P, Sidransky D, Merbs SL. Allelotype of posterior uveal melanoma: implications for a bifurcated tumor progression pathway. Cancer Res 1999; 59:3032.</a></li><li><a class="nounderline abstract_t">Shields CL, Ganguly A, Bianciotto CG, et al. Prognosis of uveal melanoma in 500 cases using genetic testing of fine-needle aspiration biopsy specimens. Ophthalmology 2011; 118:396.</a></li><li><a class="nounderline abstract_t">Gupta MP, Lane AM, DeAngelis MM, et al. Clinical Characteristics of Uveal Melanoma in Patients With Germline BAP1 Mutations. JAMA Ophthalmol 2015; 133:881.</a></li><li><a class="nounderline abstract_t">Griewank KG, Westekemper H, Murali R, et al. Conjunctival melanomas harbor BRAF and NRAS mutations and copy number changes similar to cutaneous and mucosal melanomas. Clin Cancer Res 2013; 19:3143.</a></li><li><a class="nounderline abstract_t">Haq R, Fisher DE. Biology and clinical relevance of the micropthalmia family of transcription factors in human cancer. J Clin Oncol 2011; 29:3474.</a></li><li><a class="nounderline abstract_t">Garraway LA, Widlund HR, Rubin MA, et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 2005; 436:117.</a></li><li><a class="nounderline abstract_t">Ugurel S, Houben R, Schrama D, et al. Microphthalmia-associated transcription factor gene amplification in metastatic melanoma is a prognostic marker for patient survival, but not a predictive marker for chemosensitivity and chemotherapy response. Clin Cancer Res 2007; 13:6344.</a></li><li><a class="nounderline abstract_t">Bertolotto C, Lesueur F, Giuliano S, et al. A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature 2011; 480:94.</a></li><li><a class="nounderline abstract_t">Yokoyama S, Woods SL, Boyle GM, et al. A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma. Nature 2011; 480:99.</a></li><li><a class="nounderline abstract_t">Hemesath TJ, Price ER, Takemoto C, et al. MAP kinase links the transcription factor Microphthalmia to c-Kit signalling in melanocytes. Nature 1998; 391:298.</a></li><li><a class="nounderline abstract_t">Wu M, Hemesath TJ, Takemoto CM, et al. c-Kit triggers dual phosphorylations, which couple activation and degradation of the essential melanocyte factor Mi. Genes Dev 2000; 14:301.</a></li><li><a class="nounderline abstract_t">Boni A, Cogdill AP, Dang P, et al. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res 2010; 70:5213.</a></li><li><a class="nounderline abstract_t">Haq R, Shoag J, Andreu-Perez P, et al. Oncogenic BRAF regulates oxidative metabolism via PGC1α and MITF. Cancer Cell 2013; 23:302.</a></li><li><a class="nounderline abstract_t">Bollag G, Hirth P, Tsai J, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 2010; 467:596.</a></li><li><a class="nounderline abstract_t">Joseph EW, Pratilas CA, Poulikakos PI, et al. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc Natl Acad Sci U S A 2010; 107:14903.</a></li><li><a class="nounderline abstract_t">Heidorn SJ, Milagre C, Whittaker S, et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 2010; 140:209.</a></li><li><a class="nounderline abstract_t">Poulikakos PI, Zhang C, Bollag G, et al. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 2010; 464:427.</a></li><li><a class="nounderline abstract_t">Hatzivassiliou G, Song K, Yen I, et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010; 464:431.</a></li><li><a class="nounderline abstract_t">Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364:2507.</a></li><li><a class="nounderline abstract_t">Johannessen CM, Boehm JS, Kim SY, et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 2010; 468:968.</a></li><li><a class="nounderline abstract_t">Nazarian R, Shi H, Wang Q, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010; 468:973.</a></li><li><a class="nounderline abstract_t">Tap WD, Gong KW, Dering J, et al. Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma. Neoplasia 2010; 12:637.</a></li><li><a class="nounderline abstract_t">Trunzer K, Pavlick AC, Schuchter L, et al. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol 2013; 31:1767.</a></li><li><a class="nounderline abstract_t">Montagut C, Sharma SV, Shioda T, et al. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res 2008; 68:4853.</a></li><li><a class="nounderline abstract_t">Wagle N, Emery C, Berger MF, et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol 2011; 29:3085.</a></li><li><a class="nounderline abstract_t">Wang H, Daouti S, Li WH, et al. Identification of the MEK1(F129L) activating mutation as a potential mechanism of acquired resistance to MEK inhibition in human cancers carrying the B-RafV600E mutation. Cancer Res 2011; 71:5535.</a></li><li><a class="nounderline abstract_t">Shi H, Moriceau G, Kong X, et al. Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat Commun 2012; 3:724.</a></li><li><a class="nounderline abstract_t">Whittaker SR, Theurillat JP, Van Allen E, et al. A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. Cancer Discov 2013; 3:350.</a></li><li><a class="nounderline abstract_t">Poulikakos PI, Persaud Y, Janakiraman M, et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 2011; 480:387.</a></li><li><a class="nounderline abstract_t">Villanueva J, Vultur A, Lee JT, et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 2010; 18:683.</a></li><li><a class="nounderline abstract_t">Shi H, Hong A, Kong X, et al. A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition. Cancer Discov 2014; 4:69.</a></li><li><a class="nounderline abstract_t">Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363:809.</a></li><li><a class="nounderline abstract_t">Smalley KS, Lioni M, Dalla Palma M, et al. Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas. Mol Cancer Ther 2008; 7:2876.</a></li><li><a class="nounderline abstract_t">Nathanson KL, Martin AM, Wubbenhorst B, et al. Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436). Clin Cancer Res 2013; 19:4868.</a></li><li><a class="nounderline abstract_t">Haq R, Yokoyama S, Hawryluk EB, et al. BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition. Proc Natl Acad Sci U S A 2013; 110:4321.</a></li><li><a class="nounderline abstract_t">Wilson TR, Fridlyand J, Yan Y, et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 2012; 487:505.</a></li><li><a class="nounderline abstract_t">Straussman R, Morikawa T, Shee K, et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 2012; 487:500.</a></li><li><a class="nounderline abstract_t">Solit DB, Garraway LA, Pratilas CA, et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 2006; 439:358.</a></li></ol></div><div id="topicVersionRevision">Topic 16540 Version 39.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36633525" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Cancer statistics, 2023.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36633525" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Cancer statistics, 2023.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16912270" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Malignant melanoma: genetics and therapeutics in the genomic era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17314970" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Melanocyte biology and skin pigmentation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14616056" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Genetics of hair and skin color.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17350573" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Central role of p53 in the suntan response and pathologic hyperpigmentation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20818900" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Indoor tanning--science, behavior, and policy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20952536" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Control of melanocyte differentiation by a MITF-PDE4D3 homeostatic circuit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16988713" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Topical drug rescue strategy and skin protection based on the role of Mc1r in UV-induced tanning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14695152" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26214590" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26091043" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Genomic Classification of Cutaneous Melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15870287" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Role of epidermal growth factor receptor signaling in RAS-driven melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11535809" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Suppression of Ras-mediated tumorigenicity and metastasis through inhibition of the Met receptor tyrosine kinase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19802003" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : c-Kit mutants require hypoxia-inducible factor 1alpha to transform melanocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23171796" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Elucidating distinct roles for NF1 in melanomagenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16170185" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Raf: a strategic target for therapeutic development against cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12865432" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Regulation of Raf through phosphorylation and N terminus-C terminus interaction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17635919" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : B- and C-RAF display essential differences in their binding to Ras: the isotype-specific N terminus of B-RAF facilitates Ras binding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15710605" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : B-Raf and Raf-1 are regulated by distinct autoregulatory mechanisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12068308" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Mutations of the BRAF gene in human cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16364920" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16858395" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The amino-terminal B-Raf-specific region mediates calcium-dependent homo- and hetero-dimerization of Raf.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12447372" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : High frequency of BRAF mutations in nevi.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12873977" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16845322" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : BRAF and NRAS mutations in melanoma and melanocytic nevi.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21224857" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Polyclonality of BRAF mutations in primary melanoma and the selection of mutant alleles during progression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19752400" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Polyclonality of BRAF mutations in acquired melanocytic nevi.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15781657" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16291983" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Distinct sets of genetic alterations in melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19078957" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21083380" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Mutations in GNA11 in uveal melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21051595" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Frequent mutation of BAP1 in metastasizing uveal melanomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21325067" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Large-scale analysis of KIT aberrations in Chinese patients with melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21642685" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : KIT as a therapeutic target in metastatic melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21690468" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16908931" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Somatic activation of KIT in distinct subtypes of melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18980976" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : KIT gene mutations and copy number in melanoma subtypes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6700714" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Transforming ras genes from human melanoma: a manifestation of tumour heterogeneity?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8120410" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Ras mutations in human melanoma: a marker of malignant progression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7919962" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Melanoma metastases from patients with hereditary cutaneous malignant melanoma contain a high frequency of N-ras activating mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2674680" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : N-ras mutations in human cutaneous melanoma from sun-exposed body sites.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23014346" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : BRAF mutations and KIT aberrations and their clinicopathological correlation in 202 Korean melanomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23221472" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : C-kit expression of melanocytic neoplasm and association with clinicopathological parameters and anatomic locations in Chinese people.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22817889" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : A landscape of driver mutations in melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22535154" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21343559" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26559571" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : The Genetic Evolution of Melanoma from Precursor Lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33509808" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26343582" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28783719" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23861464" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : SF3B1 mutations are associated with alternative splicing in uveal melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18719078" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Oncogenic mutations in GNAQ occur early in uveal melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25304237" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : GNAQ and GNA11 mutations in uveal melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24882515" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24713608" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Recent developments in prognostic and predictive testing in uveal melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30480620" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Molecular and immunohistochemical analyses of uveal melanoma patient cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23313955" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26923342" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Uveal Melanomas with SF3B1 Mutations: A Distinct Subclass Associated with Late-Onset Metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26683228" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Deep sequencing of uveal melanoma identifies a recurrent mutation in PLCB4.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27089179" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Recurrent activating mutations of G-protein-coupled receptor CYSLTR2 in uveal melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28810145" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28810145" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8622452" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Prognostic implications of monosomy 3 in uveal melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16988624" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : [Prognostic factors for malignant uveal melanoma. Retrospective study on 2,241 patients and recent contribution of monosomy-3 research].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9135991" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Abnormalities of chromosomes 3 and 8 in posterior uveal melanoma correlate with prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9062576" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Use of fluorescence in situ hybridization and comparative genomic hybridization in the cytogenetic analysis of testicular germ cell tumors and uveal melanomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10397238" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Allelotype of posterior uveal melanoma: implications for a bifurcated tumor progression pathway.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20869116" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Prognosis of uveal melanoma in 500 cases using genetic testing of fine-needle aspiration biopsy specimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25974357" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Clinical Characteristics of Uveal Melanoma in Patients With Germline BAP1 Mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23633454" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Conjunctival melanomas harbor BRAF and NRAS mutations and copy number changes similar to cutaneous and mucosal melanomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21670463" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Biology and clinical relevance of the micropthalmia family of transcription factors in human cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16001072" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17975146" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Microphthalmia-associated transcription factor gene amplification in metastatic melanoma is a prognostic marker for patient survival, but not a predictive marker for chemosensitivity and chemotherapy response.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22012259" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22080950" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9440696" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : MAP kinase links the transcription factor Microphthalmia to c-Kit signalling in melanocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10673502" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : c-Kit triggers dual phosphorylations, which couple activation and degradation of the essential melanocyte factor Mi.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20551059" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23477830" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Oncogenic BRAF regulates oxidative metabolism via PGC1αand MITF.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20823850" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20668238" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20141835" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20179705" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20130576" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21639808" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Improved survival with vemurafenib in melanoma with BRAF V600E mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21107320" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21107323" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20689758" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23569304" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18559533" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21383288" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21705440" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Identification of the MEK1(F129L) activating mutation as a potential mechanism of acquired resistance to MEK inhibition in human cancers carrying the B-RafV600E mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22395615" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23288408" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22113612" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21156289" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24265152" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20818844" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Inhibition of mutated, activated BRAF in metastatic melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18790768" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23833299" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23447565" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22763448" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22763439" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16273091" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : BRAF mutation predicts sensitivity to MEK inhibition.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
